Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02950454
Other study ID # 1.0
Secondary ID
Status Completed
Phase N/A
First received October 28, 2016
Last updated October 24, 2017
Start date January 2017
Est. completion date September 2017

Study information

Verified date October 2017
Source University of Glasgow
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a pilot trial to explore the cardiovascular of eight weeks of twice weekly high intensity interval training in people with progressive multiple sclerosis. A control group of people with progressive multiple sclerosis will undergo continuous moderate intensity exercise, twice weekly for 8 weeks.


Description:

This is a pilot trial to explore the cardiovascular of eight weeks of twice weekly high intensity interval training in people with progressive multiple sclerosis. A control group of people with progressive multiple sclerosis will undergo continuous moderate intensity exercise, twice weekly for 8 weeks.

The training program will entail 6x1.5 minute intervals working at 80-95% heart rate max on a cycle ergometer. Each interval will be interspersed with 1.5 minutes of working rest at a light resistance of the participant's choosing.

The continuous moderate intensity exercise program will entail 20 minutes on a cycle ergometer working at 60-70% heart rate max.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date September 2017
Est. primary completion date September 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosed with a progressive form of MS

- Aged 18 years or older

- Known to members of staff of the MS service NHS Ayrshire & Arran

- Ability to attend Douglas Grant Rehabilitation centre twice a week for eight weeks

- EDSS 4-6.0

- Able to cycle on ergometer

Exclusion Criteria:

- A relapse of symptoms requiring treatment within the past three months.

- A respiratory condition that would be exacerbated by high intensity exercise including but not limited to: chronic obstructive pulmonary disorder, uncontrolled or poorly controlled asthma.

- Uncontrolled high pressure at screening (>190/100 mmHg)

- Cognitive impairment affecting ability to understand instructions as noted in patient's notes.

- Currently engaging in another research trial for their MS or that may affect their physiological or cardiovascular outcomes

- Weighing more than 110 kg (weight limit of ergometer)

- Any pathology or medical intervention that would preclude high intensity exercise, maximal exertion testing or could attenuate the cardiovascular effect of exercise including but not limited to: unstable angina; diabetes; peripheral vascular disease or intermittent claudication; having a pace maker or medicine pump; surgical clips; having another neurological condition other than MS; and pregnancy. To be established from patient's notes and at screening session.

- A serious cardiovascular event in the past year including but not limited to: transient ischaemic attack, cerebrovascular event and myocardial infarction.

- Taking any of the following medication: beta blockers; vasodilators; ACE inhibitors; diuretics or any other medication that could cause exercise induced hypotension; hypoglycaemic insulin; metformin or other oral insulin medicine.

Study Design


Intervention

Other:
High intensity interval training
1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer
Continuous moderate exercise
20 min at 60-70% heart rate max on cycle ergometer

Locations

Country Name City State
United Kingdom The University of Glasgow Glasgow

Sponsors (3)

Lead Sponsor Collaborator
University of Glasgow AKM Stats, NHS Ayrshire & Arran

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary heart rate max Maximal heart rate elicited during a maximal exertion test 8 weeks
Secondary Resting blood pressure 8 weeks
Secondary Resting heart rate 8 weeks
Secondary Brain derived neurotrophic factor Hormone important for brain growth and protection 8 weeks
Secondary Lactate Waste materials from exercise in blood 8 weeks
Secondary Lipoprotein profile Indication of how much good and how much bad cholesterol is in blood 8 weeks
Secondary MSIS-29 version 2 Questionnaire giving physical and psychological impact of MS 8 weeks
Secondary Hospital anxiety and depression scale Questionnaire giving a score of depression and anxiety 8 weeks
Secondary Timed 25 foot walk test Measure of walking speed 8 weeks
Secondary Symbol digit modalities test Measure of mental processing speed 8 weeks
Secondary Fatigue severity scale Questionnaire which gives measure of fatigue. 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT02301247 - Treating New Learning and Memory Deficits in Progressive Multiple Sclerosis (MS) N/A